Biotech on the brink
Thursday, 05 February, 2009
A quarter of Australia’s biotechnology companies are in danger of going bust by June this year unless they receive immediate government assistance, AusBiotech CEO Dr Anna Lavelle said.
Nearly half don’t have enough cash to operate beyond 12 months, she said in a statement.
She called on the federal government for assistance through refundable tax credits, competitive matched grants and help in increasing the pool of venture capital.
She listed examples of other countries that have moved to prop up their biotech industries to ride out the credit crisis, including Norway, the UK, Canada, Japan, Germany, China and Taiwan.
“The financial crisis has put at risk a generation of small biotech companies, which are in a precarious position,” she said.
“All of our global trading partners see the sense in supporting biotechnology and are doing this.”
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
